Abstract Human induced pluripotent stem cells (hiPSC) differentiate into multiple cell types. Selective cell targeting is often needed for analyzing gene function by overexpressing proteins in a distinct population of hiPSCderived cell types and for monitoring cell fate in response to stimuli. However, to date, this has not been possible, as commonly used viruses enter the hiPSC via ubiquitously expressed receptors. Here, we report for the first time the application of a heterologous avian receptor, the tumor virus receptor A (TVA), to selectively transduce TVA ? cells in a mixed cell population. Expression of the TVA surface receptor via genetic engineering renders cells susceptible for infection by avian leucosis virus (ALV). We generated hiPSC lines with this stably integrated, ectopic TVA receptor gene that expressed the receptor while retaining pluripotency. The undifferentiated hiPSC TVA? as well as their differentiating progeny could be infected by recombinant ALV (so-called RCAS virus) with high efficiency. Due to incomplete receptor blocking, even sequential infection of differentiating or undifferentiated TVA ? cells was possible. In conclusion, the TVA/RCAS system provides an efficient and gentle gene transfer system for hiPSC and extends our possibilities for selective cell targeting and lineage tracing studies.
Introduction
Induced pluripotent cells (iPSC) have the capacity for unlimited self-renewal in vitro and for differentiation into nearly every cell type of the mammalian body [20] . As such, differentiated cells derived from human iPSC (hiPSC) are ideally suited for mode-of-action-analyses, the establishment of disease models, or pharmacological screenings [4] . Most of these applications involve genetic engineering to introduce transgenes like reporter constructs or overexpression cassettes to study for example the influence of specific genes on cell differentiation or for establishing reporter cell lines. Here, besides transfection, transduction is often considered an alternative technology as it avoids many of the stress triggers usually associated with chemical and physical transfection methods. It is currently not easily possible to selectively target specific subpopulations of cells for transfection or transduction. The ability to efficiently transduce only specific subpopulations of cells would be of benefit especially for stem cells and their differentiating progeny, for example to trigger transgene expression and monitor cell fate of only the targeted cell types in a mixed cell population.
For overexpression studies in avian cells, the avian replication competent avian leucosis virus (ALV) long terminal repeat (LTR) with a splice acceptor (RCAS) virus is a well-established tool (Fig. 1a) [1, 11] . The virus enters avian cells via interaction with the tumor virus surface receptor (TVA). Mammalian cells do not express a version of TVA that the subgroup A of ALVs can use to infect cells (Fig. 1b) . It has been shown that the range of host cell lines for the RCAS virus can be expanded to non-avian cell lines by TVA receptor expression [2, 14] . Aside from its high transduction efficiency, recombinant RCAS virus technology enables the selective targeting of TVA receptor positive (TVA ? ) cells and their tracing in a mixed cell population. Additionally, it is possible to transfer multiple genes, located on different viral vectors through co-infection [7] as well as by sequential infection, due to impaired TVA receptor blocking by the RCAS virus in infected mammalian TVA ? cells [22] . Several studies have reported the application of this TVA-RCAS system in non-avian organisms, mostly in mice [5, 21] . In 1994, Federspiel et al. were the first to generate a transgenic mouse, in which the TVA receptor was under the control of the promoter of the chicken gene skeletal muscle a-actin [5] . Thus, the TVA receptor was only expressed in skeletal muscle cells, rendering them susceptible for selective RCAS virus infection. To date, however, the extension of the RCAS overexpression system has not been applied in human iPSC, despite its potential benefit for versatile and targeted gene transfer and cell tracing of hiPSC TVA? and their progeny. The exceptional properties of the RCAS overexpression system exploits the distant genetic origin of the RCAS virus compared to other viruses usually used when working with hiPSC. The RCAS virus is a member of the avian leucosis and sarcoma virus (ALSV) family. In this study, [12] , has been used. The RCASBP(A) virus is assigned to group A because it expresses the envelope A protein (envA), enabling it to bind specifically to the TVA receptor. To facilitate overexpression studies, the oncogene virus-sarcoma (v-src) gene in this viral vector has been deleted allowing insertion of cDNA sequences with a length of up to 2.8 kb. The gene of interest is transcribed from the viral LTR. There is also another version of this RCASBP(A) virus that has no splice acceptor, which is called replication competent ALV LTR with no splice acceptor with BP virus [RCANBP(A)]. Here, the transgene expression is not driven by the LTR and to get a reliable expression of the gene of interest, introduction of a heterologous promoter into the viral genome is required.
The aim of this study was to apply the TVA-RCAS system to hiPSC, implementing the versatility of this gene transfer technology to human stem cell research. For that, we introduced the gene coding the avian TVA receptor into the genome of a hiPSC line using transposon technology (Fig. 1c) [6, 13] . Stable hiPSC TVA? clones remained pluripotent and the RCAS virus was able to infect both undifferentiated cells as well as their differentiating progeny.
Materials and methods

Cell culture
Human iPSCs (IMR90-4, WiCell, Madison, US) and hiPSC TVA? were cultured in TeSR E8 medium (StemCell Technologies, Cologne, Germany) supplemented with 100 UI/ml of each penicillin/streptomycin (Lonza, Basel, Switzerland) in six-well dishes (Costar, Washington, DC, USA) coated with Geltrex (Gibco, Paisley, UK) and routinely passaged using Gentle Cell Dissociation Reagent (StemCell Technologies) every 5-7 days at a splitting ratio of *1:6.
TVA receptor expression vector cloning
A myc-tagged TVA950 [19] has been cloned into a modified pPB-CAG.EBNXN plasmid [24] . Briefly, the PiggyBac transposon vector used contains a human EF1a promoter driving transgene expression and an additional puromycin resistance cassette. Cloning details and vector sequence are available on request.
Transfection and selection of hiPSC TVA1
For transfection, hiPSC were dissociated into a single cell suspension by treatment with accutase (Gibco) followed by washing and resuspension in TeSR E8 medium containing 10 nM ROCK inhibitor Y26732 (Wako Chemicals, Neuss, Germany). Transfection was carried out using the Neon Transfection System (Invitrogen, Carlsbad, CA, USA). Briefly, 1 9 10 5 cells were transfected with 0.5 lg total DNA consisting of PB TVA950 transposon and PB transposase [24] in a ratio of 10:1 (w/w), using 10 ll tips, settings 1.200 V for 30 ms, and one pulse. After transfection, cells were seeded in Geltrex-coated culture dishes in TeSR E8 medium. 10 nM ROCK inhibitor was added for the first 24 h of culture. After 6 days, stably transfected cells were selected by the addition of 1 lg/ml puromycin (InvivoGen, Toulouse, France) to the culture medium.
Single cell clones were isolated using the CloneStem Kit (Biolamina, Sundbyberg, Sweden), following the manufacturer's instructions. Staining of pluripotency markers was performed by fixation with Cytofix reagent, followed by blocking and permeabilization with 19 PermWash reagent (both BD) supplemented with 5 % chicken serum (Life Technologies). Thereafter, cells were incubated using anti-Nanog rabbit mAb (Cell Signaling, 1:400), followed by secondary antibody anti-rabbit Alexa Fluor594 (Life Technologies). Then, staining with the fluorescence dye-conjugated antibodies octamer transcription factor 3/4 (Oct3/4) (PerCPCy7, BD, 1:100), stage-specific embryonic antigen 4 (SSEA4) (FITC, R&D, Minneapolis, MN, USA; 1:100) and tumor rejection antigen 1-81 (Tra-1-81) (DyLight 650, Novus Biologicals, Littleton, CO, USA; 1:100) was performed. Nuclei were stained with Hoechst 33342 (2.5 lg/ ml in PBS).
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Microscopic analysis was performed with either a 2 Photon microscope (LEICA SP5 confocal microscope equipped with a Mai Tai HP multiphoton laser), or an Operetta imaging system (Perkin-Elmer), as indicated.
RCASBP(A) and RCANBP(A) cloning and production
RCASBP(A)/RCANBP(A) vectors were obtained from Stephen Hughes. Insertion of GFP, RFP, monomeric Cherry (mCherry) and the simian virus 40(SV40) promoter (Addgene accession numbers #17619, #20972, #18807, Cambridge, US) was done by performing Gibson Assembly (NEB, Hitchin, UK; described in [8] ). Primers were purchased from Eurofins (Berlin, Germany, Supplemental Table 1 ). RCASBP(A)/RCANBP(A) viruses were produced in DF1 cells (ATCC, Manassas, VA, USA) after transfection of the viral plasmids with PEI (Polysciences Inc., Eppelheim, Germany). On three consecutive days, viral particles were harvested by collecting the supernatant, followed by ultracentrifugation for high-titer concentrates. Titers were determined as plaque forming units (PFU/ml) 1 day after DF1 cell infection [15] .
Infection of hiPSC TVAs
For RCAS infection, hiPSC TVA? were cultured in 24-well plates (TPP, Trasadingen, Switzerland) or 96-well plates. Viral transduction was performed at a MOI of 50. Medium was changed every day. Two-three days post infection hiPSC TVA? were analyzed after live cell staining for nuclei (Hoechst 33342 in medium, 2.5 lg/ml in PBS) using an Operetta imaging system. Sequential infection was done 3 days apart.
Fluorescence-activated cell sorting (FACS) analysis
Cells were dissociated using Gentle Cell Dissociation Reagent and fixed with Cytofix. For Myc-tag quantification, cells were stained with anti-Myc-tag antibody (Cell Signaling, 1:2000), washed with PBS, followed by staining with secondary antibody Alexa Fluor 488 goat anti-mouse IgG secondary antibody (Invitrogen, 1:2000). Afterwards, cells were diluted in FACS buffer, consisting of 2 % bovine serum albumin (Sigma Aldrich, Seelze, Germany) and 2 mM EDTA (Sigma-Aldrich) in PBS. To quantify transduction, cells, diluted in FACS buffer, were directly used for FACS analysis, which was performed with an Accuri C6 (BD, San Jose, CA, USA). Data was analyzed with the FCS express 4 software (De Novo, Los Angeles, CA, US).
Undirected differentiation of hiPSC in 2D and 3D culture
Undirected differentiation of hiPSC TVA? in 2D culture was induced by culture in DMEM Low Glucose (Biochrom), 10 % FCS superior, 2 mM/ml L-Glutamine (Biochrom) and 100 UI/ml Penicillin/Streptomycin (Biochrom) for 3 days, following immune staining and FACS analysis.
To differentiate hiPSC TVA? in 3D culture, embryoid bodies (EBs) were generated either by cell aggregation in ultra low attachment plates (Costar) or in AggreWell plates (StemCell Technologies). Subsequently, after aggregate formation, EBs were cultured either in DMEM Low Glucose supplemented with 10 % FCS superior, 2 mM/ml LGlutamine and 100 UI/ml Penicillin/Streptomycin for 10 days or in KnockOut DMEM/F12 (Invitrogen) supplemented with 20 % KnockOut Serum Replacer (Invitrogen), 50 lM 2-Mercaptoethanol (Invitrogen), 1X MEM NonEssential Amino Acids (Invitrogen), 2 mM/ml L-Glutamine and 100 UI/ml Penicillin/Streptomycin for 7 days. The medium was changed every other day.
Splinkerette PCR
A Splinkerette PCR was performed according to Potter and Luo 2014 [18] to determine copy number and chromosomal integration site of the PB transposon. In short: genomic DNA was isolated using the Genomic DNA from tissue kit (Machery-Nagel, Dueren, Germany). One microgram of this gDNA was digested with BstYI (Fermentas, Burlington, Canada) for 2 h, followed by ligation of the resulting DNA fragments to Splinkerette oligos (sequences according to [18] , Supplemental Table 1 ). Two rounds of PCR were conducted, amplification products separated using an 1 % agarose gel (Invitrogen), and bands indicating singlecopy events were purified with the Omnipure OLS kit (Omni Life Science, East Taunton, MA, USA). These PCR products then were sequenced using a 3730 DNA Analyzer (Life Technologies; primer sequences are listed in Supplemental Table 1 ). The resulting sequence information was analyzed using the BLAT tool using the UCSC genome browser (http://genome.ucsc.edu/).
RNA isolation and quantitative PCR analysis of marker genes
Undifferentiated iPSC
TVA? and EBs were harvested and disrupted using a Shredder (Qiagen, Valencia, CA, USA), followed by RNA extraction (RNeasy Plus Mini Kit, Qiagen). One microgram of total RNA was reverse transcribed into cDNA with the TaqMan Reverse Transcription Reagents (Invitrogen). After confirming RNA integrity by 2 % agarose gel electrophoresis, cDNA was applied for quantitative analysis of trilineage differentiation potential performing quantitative PCR analysis using commercially available Taqman probes and measured on a QuantStudio 6 machine (Life Technologies, Supplemental Table 2 ). For normalization the expression of the housekeeping genes bActin, Transcriptional repressor CTCF, E1A binding protein p300 and Mothers against decapentaplegic homolog 1 (Smad1) were determined. To obtain the DCt values of the genes of interest (GOI), the mean of the housekeeping genes (ranging from 23 to 25) was subtracted from their Ct value. The DDCt value was calculated by DCt (GOI) minus DCt of the reference values of undifferentiated hiPSC TVA? .
Statistics
Statistical analysis for standard derivation of RCAS infection of hiPSC TVA? and its differentiating progeny was calculated using Prism 6 software (GraphPad, La Jolla, CA, USA). Groups consisted of three independent experiments each.
Results
Ectopic TVA receptor is located on the cell surface in human iPSC hiPSC were transfected with a PiggyBac transposon carrying the TVA receptor under the control of the housekeeping promoter elongation factor 1 (EF1). Transgene-positive cells were isolated by antibiotic selection, cloned and analyzed for single transposon integration.
TVA receptor expression in the three isolated hiPSC TVA? clones was analyzed by immunofluorescence staining of the Myc-tag fused to the extracellular c-terminus of the TVA receptor protein.
Using two-photon microscopy, expression of the TVA receptor on the cell surface of hiPSC TVA? was shown (Fig. 2a, c) . FACS analysis was performed and revealed the presence of the TVA receptor in 93.31 % of the cells (Fig. 2b) 3 days post infection (Fig. 3d) . Interestingly, after spontaneous differentiation of RCASBP(A) GFP-transduced hiPSC TVA? , viral gene expression was initiated as evidenced by GFP expression (Fig. 3a) . When differentiating cells derived from the hiPSC TVA? were infected with RCASBP(A), GFP expression was observed 72 h after infection (Fig. 3b) . In these experiments, high infection efficiencies were observed by FACS analysis, specifically 73.3 % (±7.6 %) for undifferentiated cells and 64.0 % (±7.2 %) for differentiating cells (Fig. 3e, f) .
To test the influence of the specific promoter on the transgene expression in undifferentiated hiPSC, an alternative promoter to the viral LTR for initiation of the GFP reporter gene expression was tested. When hiPSC TVA? were infected with a RCANBP(A) carrying GFP under SV40 promoter control, GFP expression was detected 72 h post infection (Fig. 3c) . FACS analysis showed an infection efficiency of 56.0 % (±13.1 %) (Fig. 3g) . GFP expression was retained upon cell differentiation (data not shown). technology, it is mandatory to confirm the continued pluripotency of the cells after the genetic engineering by introduction of the TVA cDNA. Pluripotency of the (Fig. 4) . Second, gene expression was analyzed in undifferentiated hiPSC TVA? and embryoid bodies (EBs) by quantitative RT-PCR using markers of all three germ layers. In the EBs, the expression of the ectodermal markers Paired box protein 3 (PAX3), Myosin III B (MYO3B) and Wingless-Type MMTV Integration Site Family, Member 1 (WNT1), the endodermal markers Krüppel-like factor 5 (KLF5), SRY (sex determining region Y)-box 17 (SOX17) and Hepatocyte nuclear factor 4-alpha (HNF4A) as well as the mesodermal markers Heart-and neural crest derivatives-expressed protein 1(HAND1), HAND2 and Homeodomain-only protein (HOPX) was detected. In parallel, the pluripotency markers POU domain, class 5, transcription factor 1(POU5F1/Oct 4), Nanog and sex determining region Y box 2 (Sox 2) were down regulated (Supplemental Fig. 1) .
Splinkerette PCR was performed to examine the number and position of integration sites of the PB transposon. For the hiPSC TVA? clone#1 used mostly throughout the investigation reported here, intra-intronic integration into the zinc finger matrin-type protein 4 (ZMAT4) gene was determined ( Table 1) .
Infection of human cells with RCAS vectors is highly specific to TVA expressing cells
Next we tested the application for the selective targeting of hiPSC TVA? in mixed cell populations. As a proof of concept, hiPSC TVA? were co-cultured with a stable hiPSC GFP? cell line. This mixed population was infected with a RCANBP(A) virus, containing mCherry under the control of the SV40 promoter. Microscopic analysis 3 days after infection revealed that expression of the fluorescent proteins on the cellular level was mutually exclusive. In consequence, only GFP-negative hiPSC TVA? were infected by the mCherry encoding RCAN virus, as evident from cell clusters of the respective hiPSC subpopulations growing into each other (Fig. 5) .
Moreover, sequential infection with two RCAS viruses at different time points was possible. This has been tested in hiPSC TVA? (data not shown), as well as their differentiating progeny (Fig. 5b) . Here, hiPSC TVA? were first infected with a RCAS RFP virus, followed by infection with a RCAS GFP virus 3 days later.
Discussion
The aim of this study was to establish the avian leukosis virus (ALV)-based retroviral vector TVA-RCAS system for human iPSC, expanding its reach to stem cell research. 
To establish and evaluate the TVA-RCAS system in stem cells, we generated hiPSC clones expressing the TVA receptor gene, evaluated the presence and functionality of the receptor, confirmed their continued pluripotency and lastly characterized the potency of the system by determining the infection efficiency and selectivity in a mixed cell population using RCAS viral vectors.
In our study, we were able to stably transfect and express the TVA receptor in hiPSC using a PiggyBac transposon, taking advantage of the high chromosomal integration activity of this gene transfer system [23] . There was no obvious effect on pluripotency subsequent to the genetic manipulation of the hiPSC. As previously described in the literature, the EF1 promoter proved to be suitable for high ectopic gene expression in hiPSC, as well as in their differentiating progeny [9, 16] . Correct localization of the TVA receptor on the cell surface and susceptibility of hiPSC TVA? for the RCAS virus were verified. However, viral gene expression in hiPSC TVA? turned out to be problematic as RCAS-vector-based GFPtransgene expression was not detected in hiPSC TVA? after infection when using the viral LTR for gene overexpression (Fig. 3d) . One explanation could be that the hiPSC are not permissive for the RCAS virus. This possibility was ruled out by showing that LTR-driven GFP transgene expression started after differentiation of hiPSC TVA? infected with a RCAS vector. Another explanation could be the lack of functionality of the viral LTR in hiPSC. Our study suggests that this is the case, as we were able to overcome this problem by using the heterologous SV40 promoter in a modified RCAS version, the RCAN virus.
We also tested the EOS-C 3? (Early transposon promoter and Oct4 and Sox2 enhancers) [10] , Thymidine Kinase (TK) [17] , and CMV promoters, which were functional in initiating ectopic gene expression in hiPSC, but gene expression was lower compared to SV40 (data not shown).
When using the EF1 and Cytomegalovirus (CMV) early enhancer/chicken beta actin (CAG) promoters, there was no functional RCAN virus production even in the DF1 production cell line. As both promoters contain intron sequences, these could be recognized by the mammalian splicing apparatus and removed before genome integration, explaining the missing promoter function. While such an effect might contribute to the observed phenotype, this potential explanation remains speculative, and has not been further examined in the current study.
We observed higher viral transgene expression in differentiating hiPSC TVA? progeny than in undifferentiated hiPSC TVA? . This might be explained by increased silencing of retroviral DNA in hiPSC after integration into the genome. Whatever the mechanism, the RCAS vector system introduced here provides not only the opportunity for infection with at least two different viral constructs but also for multiple re-infection at later time points. This enhances the utility of the RCAS viruses for e.g., lineage tracing. The unusual possibility for subsequent transductions is most likely due to incomplete blocking of the TVA receptors by EnvA protein on the cell surface, since there is no sufficient viral protein production in non-avian cells [22] . The final purpose of this study was to confirm selectivity of RCASBP(A) infection towards hiPSC TVA? in a mixed cell population, which could be shown accurately, when co-culturing hiPSC TVA? with hiPSC stably expressing GFP followed by infection with a RCANBP(A) SV40 mCherry virus. This highlights one uniqueness of this newly designed tool: most of the commonly used retro-and lentiviral vector systems used for stem cell transduction enter cells by interactions of the vesicular stomatitis virus glycoprotein (VSV-G protein) and the corresponding receptor, which is ubiquitously present on mammalian cell membranes and therefore makes selective infection impossible [3] . In contrast to that, RCAS virus infection is guarded by the EnvA protein [11] recognizing the TVA receptor. Therefore, cellular selectivity for the RCAS virus is given, after ectopic TVA receptor expression [2, 5] .
Taken together, a novel tool for the efficient transduction of hiPSC was developed. We foresee the selective targeting of defined subpopulations of cells, either in mixed stem cell cultures or in lineage tracing experiments, as well as possible sequential infection as main areas of application for this technology.
Conclusions
In this study we report for the first time the successful application of the TVA-RCAS system for efficient infection of hiPSC. It represents a promising new avenue for generating genetically engineered stem cells via viral transduction for differentiation, cell fate, and gene-function studies. The TVA-RCAS system has the added value of selective targeting hiPSC TVA? in mixed populations as well as sequential infection with different viruses. Selective cell targeting and lineage tracing of human induced pluripotent stem cells using recombinant… 4679
